Mathew Aby J. 4

4 · BIOLIFE SOLUTIONS INC · Filed Feb 26, 2026

AI-generated summary of this filing

Updated Feb 26, 2026

BioLife (BLFS) EVP Mathew Aby Receives Award; Shares Withheld

What Happened

Mathew Aby, EVP & Chief Scientific Officer of BioLife Solutions (BLFS), received restricted stock awards on Feb 24, 2026 totaling 59,701 shares (20,096 shares and 39,605 shares). To cover tax withholding on vesting, 15,585 shares were withheld/disposed at $22.65 each, totaling about $353,000.
These were compensation awards (not an open-market purchase or voluntary sale). One award is a time-based restricted stock grant tied to 2026 compensation and the other was a market-based award that vested at approximately 156% of the original grant based on relative total shareholder return.

Key Details

Transaction date: 2026-02-24; Form 4 filed 2026-02-26 (timely within typical two-business-day window).
Grants: 20,096 shares (time-based restricted stock) and 39,605 shares (market-based/performance restricted stock).
Tax withholding: 15,585 shares withheld/disposed to satisfy tax obligations at $22.65/share, amounting to ~$353,000 (footnote indicates withholding relates to the vested market-based award).
Plan: Awards granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan.
Shares owned after the transaction: not specified in the provided filing.

Context

This filing reflects compensation-related awards and routine tax withholding — common for vesting restricted stock — rather than a buy or a proactive sale signaling a trading decision.
The market-based award’s payout level (≈156%) was determined by BioLife’s total shareholder return relative to peer companies for 1/1/24–12/31/25, per the filing.

Form 4

Period: 2026-02-24

EVP & Chief Scientific Officer

Transactions

Footnotes (3)

[F1]The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.
[F2]The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
[F3]Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Signature

/s/ Aby J. Mathew|2026-02-26

1 file